From supportive nutrition to therapeutic nutrition
==================================================

In patients who are critically ill, there is no doubt that nutritional status and clinical outcome are linked \[[@B1]\]. ICU patients typically experience catabolic stress and systemic inflammatory response; in turn, these responses alter both the morphology and function of the gastrointestinal (GI) tract \[[@B2]\]. Up to 60% of ICU patients suffer GI dysfunction due to impaired GI motility, digestion, or absorption \[[@B3],[@B4]\]. Such GI dysfunction, often coupled with inadequate caloric intake, leads many critically ill patients to develop an energy deficit and lose lean body mass \[[@B5]-[@B10]\].

ICU patients with poor nutritional status commonly experience immune dysfunction, weakened respiratory muscles and lowered ventilation capacity, and reduced GI tolerance \[[@B11],[@B12]\]. As a result, patients are at risk for a wide range of complications: ventilator dependence; GI dysfunction with gastroesophageal reflux, esophagitis, or pulmonary aspiration; and infections that can lead to sepsis, multi-organ failure, and even death \[[@B1],[@B12],[@B13]\]. For such patients, supportive nutrition has long been used as adjunctive care; however, such nutrition is often inadequate, including only fundamental macronutrients to sustain patients through periods of metabolic stress.

Feeding an ICU patient now extends beyond choosing the right feeding route, the rate, and the caloric density. In modern critical care, the paradigm of \'therapeutic nutrition\' is replacing traditional \'supportive nutrition\' \[[@B14]\]. Enteral feeds are now formulated with active nutrients that may help reduce oxidative damage to cells and tissues, modulate inflammation, enhance beneficial stress responses, and improve feeding tolerance.

In this review, we summarize the most recent data on feeding critically ill patients. We describe practice guide-lines established by US, European and Canadian enteral and parenteral nutrition societies, beginning with recommendations of how to feed (enteral, parenteral, or both) and when to feed (early versus delayed start). We systematically discuss what to feed critically ill patients by reviewing mechanisms of action for specific pharmaconutrients and by concisely summarizing current guide-lines and expert recommendations for feeding various populations in the ICU. We compile clinical evidence on feeding anti-inflammatory, immune-modulating, and GI tolerance-promoting nutritional formulas in specific patient subgroups. Finally, we introduce a straightforward algorithm to help bedside clinicians make feeding decisions for patients with critical illness.

The basics: how and when to initiate feeding in ICU patients
============================================================

Many ICU patients are incapable or intolerant of a food diet; therefore, a clinician\'s first nutritional decision is whether to tube-feed enterally, parenterally, or with a combination of both.

Practice guidelines in Europe, Canada, and the US endorse enteral feeding for patients who are critically ill and hemodynamically stable \[[@B1],[@B11],[@B15]\]. Enteral nutrition is preferred over parenteral nutrition (PN) for most ICU patients - an evidence-based practice supported by numerous clinical trials involving a variety of critically ill patient populations, including those with trauma, burns, head injury, major surgery, and acute pancreatitis \[[@B1],[@B16]\]. For ICU patients who are hemodynamically stable and have a functioning GI tract, early enteral feeding (within 24 to 48 hours of arrival in the ICU) has become a recommended standard of care \[[@B1],[@B11],[@B15]\]. Experts identify these early hours as a window of opportunity to provide nutrition that maintains gut barrier function and supports immune responses \[[@B1],[@B11]\].

Patients with extreme hemodynamic instability - with rising plasma/blood/serum lactate concentrations or escalating requirements for vasopressors - are generally not considered candidates for enteral feeding. However, early findings suggest use of early enteral feeding in other vasopressor-dependent patients. In one study, vasopressor-dependent patients who were given enteral feeding within the first 48 hours had a significant survival advantage compared to those whose feeding was delayed; in fact, the sickest patients (on multiple vasopressors) experienced the greatest benefit \[[@B17]\]. It should be noted that this finding is based on an observational study. A confirmatory prospective, controlled study is warranted.

Even though early enteral nutrition is favored for most ICU patients, caloric and protein needs are often not met by enteral feeding \[[@B10]\]. Nutritional intake may be hampered by setting target levels too low, interruption of feeding for procedures, issues of airway management, and poor tolerance of feedings \[[@B8],[@B18],[@B19]\]. To enhance use of enteral feeding in ICU patients, several feeding strategies have been proposed recently: shift from an hourly-rate feeding goal to a 24-hour volume goal, allowing nurses to \'make-up\' for interruptions and meet feeding targets \[[@B20]\]; accept gastric residual volumes up to 500 mL to increase the volume of formula delivered in practice \[[@B1],[@B20]-[@B22]\]; and use a promotility agent to help reduce gastric residual volume \[[@B20],[@B21],[@B23]\].

PN is necessary in critically ill patients who do not have an intact GI tract, but current guidelines do not agree on when to initiate PN \[[@B5]\]. For patients who are intolerant or have other contraindications to enteral feeding, European guidelines recommend starting PN within 24 to 48 hours if the patient is not expected to be on oral nutrition within 3 days \[[@B24]\]. US guidelines hesitate to recommend PN on admission to the ICU; standard care (intravenous fluids) is recommended first, with PN reserved and initiated only after 7 days in well-nourished patients \[[@B1]\]. Both the European Society for Parenteral and Enteral Nutrition (ESPEN) and American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines recommend early PN use (within 24 hours of ICU admission) in patients who are malnourished \[[@B1],[@B24]\]. Canadian guide-lines state that PN should not be used in any patient with an intact GI tract \[[@B25]\].

When enteral feeding alone is inadequate, some experts are calling for use of PN and enteral nutrition together to meet energy and protein targets \[[@B5],[@B7],[@B26],[@B27]\]. Combination regimens are justified by observations that actual enteral intake typically meets only half of prescribed calories in ICU patients \[[@B6],[@B8]-[@B10]\]. For patients who are expected to be mechanically ventilated for more than 72 hours and have body mass index (BMI) scores \<25 or ≥35, each additional 1,000 kcal/day or 30 g protein/day was reported to be associated with reduced mortality \[[@B27]\].

However, clinical evidence for combination feeding remains unclear. Two recent randomized trials have helped clarify this subject. Casaer and colleagues \[[@B28]\] conducted a large, single center prospective, randomized trial (EPaNIC trial) comparing outcomes in critically ill patients on enteral nutrition who had early versus late initiation of PN (early, \<48 hours after ICU admission, *n*= 2,312; late, day 8 or later after ICU admission, *n*= 2,328). Results revealed patients on late-initiation PN had a relative increase of 6% in the likelihood of being discharged alive earlier from the ICU and from the hospital (*P*= 0.04). Those in the late-initiation group also had significantly fewer ICU infections, shorter duration of mechanical ventilation and a shorter course of renal replacement therapy. Several aspects of the study limit generalizability of the findings to all ICU populations. First, patients with chronic malnutrition were not included in the study. Second, the trial PN formulation did not contain either glutamine or immune-modulating ingredients, nor was there any adjustment for presence/absence of immune-modulating ingredients in enteral feedings. Third, patients in the trial received a low protein delivery (median of 0.8 g/kg/day protein (after day 3)) for the study period in the early PN group; this protein target is below what is recommended by most guidelines for critically ill patients (the typical recommendation is 1.3 to 1.5 g/kg/day (ESPEN guidelines)). Finally, the trial examined a low mortality-risk patient group with an average ICU mortality of 6.2% (90-day mortality of 11.2%) and a relatively low severity patient group with an ICU length of stay of 3.5 days, and a mechanical ventilation period of 2 days. Accounting for the aforementioned limitations, The EPaNIC trial is unquestionably a key contribution to the literature on supplemental PN use in critical care. We believe the key conclusion is that early aggressive calorie delivery via PN does not appear to be beneficial in low mortality risk, non-chronically malnourished patients. In contrast, the recently published, single center TICACOS trial showed hospital and 60-day mortality was reduced (*P*\< 0.02 for both time points) in a higher mortality risk group of ICU patients receiving additional calories via enteral nutrition supplemented with PN \[[@B29]\]. In comparison to the EPaNIC trial, the TICACOS trial was conducted in a higher risk ICU patient group with an ICU mortality of 25.4% (60-day mortality of 47%), ICU length of stay of 12 days, and a mechanical ventilation period of 10.75 days. Thus, it is possible that supplemental PN may improve outcome in high mortality risk ICU patients. Additional trials on the use of enteral nutrition with supplemental PN have recently been completed or are underway. These forth-coming results should continue to clarify the utility of supplemental PN use in the ICU.

Choosing which enteral formulation to feed
==========================================

For most ICU patients, the next decision is what enteral formula to feed. Critically ill patients are a heterogeneous population, so no one-size-fits-all nutritional formula should be expected \[[@B30],[@B31]\]. Feeding formulas to consider are anti-inflammatory, immune-modulating, GI tolerance-promoting, and standard enteral nutrition.

What are the key functional pharmaconutrients in enteral formulas?
------------------------------------------------------------------

Guidelines from professional nutrition societies around the world identify certain populations of patients who can benefit from formulations with specific pharmaconutrients \[[@B1],[@B11],[@B15],[@B25]\]. For many others, each physician must use his or her own clinical judgment about what formula will best meet the patient\'s needs. To help guide such choices, the following section reviews functional pharmaconutrients and their roles in critically ill patients.

### *Anti-inflammatory enteral nutrients*

Critical illness and injury are characterized by oxidative stress and excessive inflammation, harmful processes that damage cells and impair function of vital organs. Extreme inflammation - as in patients with systemic inflammatory response syndrome (SIRS), sepsis, acute lung injury (ALI), or acute respiratory distress syndrome (ARDS) - often progresses to multiple organ dysfunction syndrome and even death. Feeding formulas with specific pharmaconutrients can help o set tissue damage and moderate inflammation. Dietary antioxidants (vitamins A, C, and E and selenium) play important roles in reducing potential for tissue damage by stabilizing free radicals in cells, while dietary fish oil and borage oil blunt out-of-control inflammatory responses by modulating synthesis of pro- and anti-inflammatory mediators \[[@B31]-[@B33]\].

#### Fish oil and borage oil

Dietary intake of certain oils alters the fatty acid composition in membranes of cells involved in immune inflammatory responses, that is, neutrophils and macrophages. Certain cell membrane fatty acids (for example, arachidonic acid (AA)) serve as precursors to inflammatory eicosinoids and leukotriene mediators, while other fatty acids (eicosapentaenoic acid (EPA), docosohexaenoic acid (DHA), gamma linolenic acid (GLA)) are metabolized to form less pro-inflammatory mediators \[[@B31]-[@B34]\]. In addition, DHA and EPA are precursors of resolvins and protectins, which help resolve inflammation and reduce tissue injury \[[@B35]\].

Fish oils are rich in the ω-3 fatty acids EPA and DHA, the active metabolites of alpha-linolenic acid \[[@B31]-[@B33]\]. While healthy humans have desaturase enzymes that convert alpha-linolenic acid to EPA and DHA, such conversion is negligible in individuals who are critically ill. As a result, enteral nutrition containing EPA and DHA can help quell excessive inflammatory responses. The anti-inflammatory actions of the ω-3 fatty acids EPA and DHA are thought to occur by (1) blunting production of pro-inflammatory mediators as a result of replacing AA in macrophage and neutrophil membranes, (2) blocking synthesis of pro-inflammatory mediators from AA by competing for the metabolic enzymes cyclooxygenase and lipoxygenase, and (3) supporting production of less inflammatory prostaglandin and leukotriene mediators \[[@B34]\] (Figure [1](#F1){ref-type="fig"}). Oil from the borage plant contains GLA, an ω-6 fatty acid that similarly competes with proinflammatory AA for conversion enzymes; GLA is a precursor to mediators that are less inflammatory than the prostaglandins and leukotrienes produced from AA \[[@B31]\].

![**Specific dietary fatty acids, eicosapentaenoic acid (EPA) and gamma linolenic acid (GLA), limit excessive inflammation by competing with enzymes involved in conversion of membrane-derived arachidonic acid (AA) to proinflammatory mediators**. As a result, alternative mediators, which are less inflammatory, are produced. PGE, prostaglandin.](cc10430-1){#F1}

Results vary in studies using fish oil-supplemented enteral formulas in critically ill patients, partly because of the different formulations and doses of fish oil. However, an enteral formula containing EPA and GLA consistently showed significant benefits in three studies of mechanically ventilated patients with ALI/ARDS or severe sepsis/septic shock \[[@B36]-[@B38]\] (Figure [2](#F2){ref-type="fig"}). Use of this anti-inflammatory feeding formulation significantly reduced time on ventilator, ICU and hospital lengths of stay, and incidence of new organ failure. Further, a meta-analysis performed by the authors of the original trials showed that the use of a fish-oil-containing formula significantly reduced the risk of 28-day mortality by 49% compared to a high fat control enteral formulation \[[@B39]\]. Results of another large meta-analysis showed that immune-modulating formulas containing fish oil significantly reduced by half the risk for mortality and secondary infections and significantly shortened length of hospital stay by more than 6 days in ICU patients with ALI/ARDS or severe sepsis/septic shock; such significant benefits were not seen in trauma and burn patients \[[@B40]\]. Moreover, a recent study of critically ill mechanically ventilated, septic patients (not all of whom had ARDS) found that feeding a formula enriched with EPA, GLA, and antioxidants shortened ICU stay but did not show benefits in terms of infectious complications, gas exchange, or organ failures \[[@B41]\].

![**Formulas containing eicosapentaenoic acid (EPA) and gamma linolenic acid (GLA) moderate uncontrolled inflammation, while formulas with arginine lessen immune suppression**. With feeding of these specific pharmaconutrients, complications of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and sepsis or surgery, burns, and trauma can be prevented or blunted, thereby lessening adverse outcomes. MODS, multiple organ dysfunction syndrome.](cc10430-2){#F2}

#### Antioxidant nutrients

Antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) - in association with selenium, zinc, manganese, and iron - provide intrinsic defense mechanisms to remove reactive oxygen species generated by everyday living \[[@B33]\]. However, critical illness or injury leads to increased oxidative stress, and these enzymes and their cofactors can be depleted.

In critical illness, patients with a history of deficient dietary intake of antioxidant vitamins were more likely to suffer redox imbalance than were those whose anti-oxidant vitamin intake was near the recommended daily allowance \[[@B42]\]. Repletion studies showed that survival was improved when such patients were given supplemental antioxidant vitamins and minerals and trace elements (for example, vitamins A, C and E, selenium, copper, and zinc) \[[@B25],[@B43]\]. A multi-center study showed reduced mortality rates when patients were given high-dose selenium by intravenous supplementation \[[@B44]\]. There were two limitations to this multi-center study: specifically, the reduction in mortality with selenium was only apparent when data were analyzed as per-protocol, and the number of exclusions was substantial.

### *Immune-modulating enteral nutrients*

Arginine, glutamine and nucleotides are conditionally essential nutrients that can be depleted by stresses of critical illness and injury. These nutrients usually support immune homeostasis by maintaining the functional integrity of immune cells and helping in wound healing and tissue repair processes. With nutritional deficits, the function of the immune system is impaired. For instance, arginine deficiency develops in patients who have experienced surgery or trauma \[[@B45]\]. Glutamine deficiency occurs in many ICU patients, including those with sepsis, trauma, surgery, or burns \[[@B31],[@B33],[@B46],[@B47]\]. Similarly, during times of stress and rapid cell proliferation, nucleotide availability may be rate-limiting for synthesis of nucleotide-derived compounds. In the next sections, we review pivotal roles of these three nutrients in modulating immune responses.

#### Arginine

Arginine is a conditionally essential amino acid that is supplied by the diet, synthesized endogenously, and salvaged from body proteins \[[@B45]\]. It supports polyamine synthesis (for cell growth and proliferation), proline synthesis (for wound healing), and is a biosynthetic substrate for nitric oxide (a signaling molecule for immune and other cells) \[[@B31],[@B33],[@B45]\].

Results of recent investigations revealed how immune function is tied closely to arginine metabolism \[[@B49]\]. Soon after injury or surgery, immature cells of myeloid origin appear in the circulation and in lymph tissues. These cells produce arginase-1, an enzyme that breaks down arginine. Increased arginine breakdown, coupled with low intake and limited endogenous production, results in overall arginine deficiency. This deficiency is associated with suppression of T-lymphocyte function. T-lymphocyte dysfunction after surgery or trauma is characterized by a decrease in the number of circulating CD4 cells, blunted T-cell proliferation, decreased production of IL-2 and interferon gamma, and loss of the zeta (ζ) chain, a peptide essential in the T-cell receptor complex \[[@B48]\].

Results of several clinical studies showed that repletion of arginine, along with ω-3 fatty acids, helps restore T-lymphocyte numbers and function - that is, CD4 cell counts and IL-2 production \[[@B48],[@B49]\]. Dietary ω-3 fatty acids also blunt expression of arginase 1 \[[@B50]\]. Thus, substantial evidence supports the concept that immune-modulating diets exert their beneficial effects by restoring T-cell function that was impaired by arginine depletion.

Clinical outcome data (30 trials; 3,000 patients) showed a significant treatment effect of arginine supplementation following major surgery; arginine treatment reduced the risk of infection (relative risk = 0.58; 95% confidence interval (CI) of 0.48 to 0.69; *P*\< 0.00001) and overall length of stay (weighted mean difference = -2.09; 95% CI of -3.20 to -0.97; *P*= 0.0002) versus standard enteral nutrition \[[@B51]\]. In addition, arginine (at doses given in immune-modulating nutrition, 12 to 15 g/day) is potentially helpful for patients for 5 to 7 days prior to major surgery (as studied in abdominal, ear/nose/throat, and cardiac surgery) \[[@B45],[@B51]\]. However, very little benefit, and perhaps harm, is observed in patients with severe sepsis \[[@B52],[@B53]\]. This potential harm may be caused by promotion of excessive nitric oxide production in patients with sepsis, in turn worsening SIRS and increasing risk for mortality \[[@B54]\]. Nevertheless, these mechanisms are considered expert opinions rather than proven effects. For instance, lesser doses of arginine (6 g intravenously or orally) appear to have undetectable effects on blood pressure in healthy subjects \[[@B55]\].

Taken together, clinical evidence supports the concept that arginine-containing formulas should be considered as a standard of care in the peri-operative period, that is, both before and after major surgery (Figure [2](#F2){ref-type="fig"}). Trauma and post-myocardial infarction patients, and those with pulmonary hypertension may also benefit from supplemental arginine following injury \[[@B45]\]. For patients with severe sepsis, arginine-supplemented enteral formulas should be used with extreme caution \[[@B1]\] or avoided due to potential harm \[[@B15],[@B25],[@B40],[@B54]\].

#### Glutamine

Glutamine is the most abundant free amino acid in the body, but its stores are rapidly depleted during critical illness or injury, including burns \[[@B31],[@B46],[@B56]\]. Glutamine serves as a metabolic substrate for enterocytes and immune cells, thus supporting intestinal barrier function and immune responses \[[@B56]\]. Glutamine was recently proposed to serve as a signaling molecule in states of illness and injury, that is, a messenger to turn on genes involved in cell protection and immune regulation \[[@B57]\].

Glutamine is expected to have the greatest benefit in severely ill patients with sepsis and organ failure, that is, those with the most severe glutamine deficiency. Further, glutamine deficiency at ICU admission has been correlated with increased mortality \[[@B58]\]. Clinical evidence for glutamine-supplemented parental nutrition comes from randomized controlled trials (900 patients; 4 level 1 and 13 level 2 randomized controlled trials); together these studies show significant reductions in mortality, infection, and hospital length of stay \[[@B25]\]. Glutamine use is supported by clinical nutrition guidelines worldwide \[[@B1],[@B11],[@B15],[@B25]\].

Enteral formulations with glutamine appear to benefit patients with burns or trauma \[[@B25]\]. Benefits are dose-dependent, with \>0.3 g/kg/day required for benefit; 0.5 g/kg/day (in divided portions) may be more effective \[[@B25]\]. A meta-analysis of all glutamine randomized controlled trials (both enteral and parenteral) showed a statistically significant reduction in mortality in ICU patients of all types (21 studies, more than 1,500 patients) \[[@B25]\]. More data are needed to support the routine use of enteral glutamine in other critically ill patients.

#### Nucleotides

Nucleotides play an active role in cell proliferation and immune modulation. They are low molecular weight, intracellular compounds that serve as building blocks for DNA, RNA, and ATP, and are components of several key metabolic coenzymes \[[@B33]\]. Nucleotides can be synthesized *de novo*, or they can be retrieved through salvage pathways. During times of stress and rapid cell proliferation, nucleotide availability may be rate-limiting for synthesis of nucleotide-derived compounds. Dietary supplies help compensate for these shortfalls, in turn supporting cell proliferation, differentiation, and function, especially for cells of the immune system \[[@B33]\]. Evidence for benefits of dietary nucleotides comes from preclinical studies, so clinical outcome trials are still needed. While nucleotides are unlikely to cause harm, their inclusion in therapeutic nutrition cannot yet be recommended.

### *Tolerance-promoting prebiotic formulas*

Enteral-feeding intolerance is common in critically ill patients \[[@B59]\]. Such intolerance is attributed to illness-associated intestinal dysfunction, such as impaired motility, inadequate digestion, and reduced absorption, as well as to side effects of treatment drugs. Half of all ICU patients on enteral nutrition have some symptoms of intolerance, that is, increased residual volume, bowel dilation, vomiting, or diarrhea \[[@B3],[@B4]\]. About 80% of patients with head injury and 50% of mechanically ventilated and post-surgical patients have delayed gastric emptying \[[@B60]-[@B62]\].

Certain diseases and conditions predispose patients to GI problems. Not surprisingly, abdominal surgery contributes to GI tract dysfunction, including laparoscopic procedures where the gut is not handled at all \[[@B63]\]. Patients with burns and traumatic injuries may experience GI motility problems \[[@B63],[@B64]\]. In sepsis, exocrine pancreatic function is reduced, which can impair protein digestion \[[@B65]\]. Treatments for cancer and other conditions - for example, opiates, radiotherapy, or chemotherapy - have side effects of anorexia and impaired GI function \[[@B66]\].

In such situations, tolerance-promoting enteral formulas are a rational feeding choice. Enteral formulas with extensively hydrolyzed proteins, that is, peptide-based feeding formulas, can be fed to patients intolerant of whole proteins. Enterocytes normally absorb small peptides (primarily di- and tripeptides), so proteins do not need to be fully digested to single amino acids for uptake \[[@B67]\]. It will be important to confirm that this mechanism for peptide uptake remains active in critically ill patients.

Further, tolerance-promoting formulas often supply fats as medium-chain triglycerides, that is, lipids that are small enough to be water-soluble with little or no bile salt. Compared to long-chain fats, the medium-chain triglycerides appear to be tolerated because they are quickly absorbed by the intestine and metabolized by the liver. The length of a fatty acid chain may influence gastric emptying, at least in part, via a reduction in GI hormones such as cholecystokinin and glucagon-like peptide-1 \[[@B68]\].

Prebiotic ingredients also help improve GI tolerance of enteral formulations; prebiotics are non-digestible food ingredients, mainly carbohydrates, that stimulate growth of beneficial bacteria in the digestive system, in turn benefiting the health of the host \[[@B69],[@B70]\]. In one study of patients with acute pancreatitis, feeding an enteral formula with prebiotics (a mix of fructooligosaccharides and other soluble and insoluble fibers) significantly improved clinical outcomes and lessened disease severity compared to feeding a fiber-free formula \[[@B71]\]. More studies are warranted and needed to determine the clinical effects of prebiotic-supplemented enteral formulations in critically ill patients \[[@B72]\].

Expert guidelines for therapeutic enteral nutrition in the ICU
--------------------------------------------------------------

Evidence-based nutrition guidelines for critically ill patients have been developed in North America and Europe \[[@B1],[@B15],[@B25]\]. While the guidelines agree in principle regarding pharmaconutrients, there are some differences in specific recommendations (Table [1](#T1){ref-type="table"}).

###### 

Summary of expert recommendations on harm/benefit of specific ingredients in feeding formulas by population of critically ill patients \[[@B1],[@B15],[@B25]\]

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients                      CCCPG                                                                                                                                                                ESPEN                                                                                                                            ASPEN/SCCM
  ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  General                       Arginine (no benefit)\                                                                                                                                               No recommendation\                                                                                                               Antioxidants (possible benefit)\
                                No recommendation\                                                                                                                                                   No recommendation\                                                                                                               Glutamine (possible benefit)\
                                Antioxidants (possible benefit)                                                                                                                                      No recommendation                                                                                                                Antioxidants (benefit)

  Elective surgery              No recommendation                                                                                                                                                    Arginine (benefit)                                                                                                               Arginine (benefit)

  Trauma                        Arginine (no benefit)\                                                                                                                                               Arginine (benefit)\                                                                                                              Arginine (benefit)\
                                Glutamine (possible benefit)\                                                                                                                                        Glutamine (benefit)\                                                                                                             Glutamine (possible benefit)\
                                No recommendation                                                                                                                                                    No recommendation                                                                                                                Antioxidants (benefit)

  Burns                         Arginine (no benefit)\                                                                                                                                               No recommendation\                                                                                                               Arginine (benefit)\
                                Glutamine (possible benefit)\                                                                                                                                        Glutamine (benefit)\                                                                                                             Glutamine (possible benefit)\
                                No recommendation                                                                                                                                                    Antioxidants (benefit)                                                                                                           Antioxidants (benefit)

  Sepsis                        Arginine (harm)\                                                                                                                                                     Arginine (harm if severe sepsis; benefit if mild)\                                                                               Arginine (harm if severe sepsis; benefit if mild/moderate)\
                                No recommendation                                                                                                                                                    No recommendation                                                                                                                Antioxidants (benefit)

  ALI/ARDS                      ω-3 fatty acids and ω-6 gamma-linolenic acid (benefit)\                                                                                                              ω-3 fatty acids (benefit)\                                                                                                       ω-3 fatty acids and ω-6 gamma-linolenic acid (benefit)\
                                Arginine (no benefit)\                                                                                                                                               No recommendation\                                                                                                               No recommendation\
                                No recommendation                                                                                                                                                    Antioxidants (benefit)                                                                                                           Antioxidants (benefit)

  Enteral feeding intolerance   Whole-protein formulas for most patients; hydrolyzed protein formula may be considered for patients with GI dysfunction such as short bowel syndrome, pancreatitis   Whole-protein formulas for most patients; hydrolyzed protein formula may be considered for GI dysfunction such as pancreatitis   Hydrolyzed protein formula may be considered for patients with GI dysfunction such as persistent diarrhea, pancreatitis
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASPEN, American Society for Parenteral and Enteral Nutrition; CCCPG, Canadian Critical Care Practice Guidelines; ESPEN, European Society for Clinical Nutrition and Metabolism; GI, gastrointestinal; SCCM, Society of Critical Care Medicine.

### Enteral formulas with anti-inflammatory nutrients

Enteral formulas supplemented with inflammation-moderating fats (ω-3 fish oils DHA and EPA, and ω-6 borage oil GLA) and antioxidants are recognized in evidence-based guidelines to blunt inflammatory responses and protect against free radical damage \[[@B1],[@B15],[@B25]\]. All guidelines specifically recommend the use of ω-3 fatty acids in ALI/ARDS patients \[[@B1],[@B15],[@B25]\], and all guidelines support enrichment of antioxidant vitamins and trace elements in enteral formulas \[[@B1],[@B15],[@B25]\].

### *Enteral formulas with immune-modulating nutrients*

Formulas with immune-modulating nutrients, such as arginine, glutamine, and possibly nucleotides, support immune responses and lower risks of infectious complications in many patients. While some recommendations group these nutrients together, recent findings identify specific indications for each nutrient.

Enteral formulations with arginine are recommended for surgical patients \[[@B1],[@B15]\]. By contrast, guidelines advise using arginine with caution in patients who are experiencing inflammatory responses following infection, such as those with severe sepsis or septic shock, due to arginine\'s potential for increasing endogenous production of nitric oxide \[[@B1],[@B15],[@B25]\].

Glutamine-supplemented enteral nutrition is specifically recommended for burn and trauma patients; glutamine is recommended for all patents on PN \[[@B1],[@B15],[@B25]\].

Nucleotides may be conditionally essential for cell proliferation during times of metabolic stress, but only European and US guidelines mention theoretical benefits from nucleotide supplementation in immune-modulating formulas \[[@B1],[@B15]\]. Canadian guidelines do not support this practice \[[@B25]\].

### *Enteral formulas designed to promote gastrointestinal tolerance*

Peptide- and medium-chain triglyceride-based formulas with prebiotics lessen GI tolerance problems related to enteral nutrition. Guidelines specifically recommend hydrolyzed protein formulas for patients with GI dysfunction, such as short bowel syndrome, pancreatitis, or persistent diarrhea \[[@B1],[@B15],[@B25]\]. Guidelines have not yet made recommendations regarding fiber content for enteral feeding in the ICU.

Choosing the right feeding formula for an ICU patient
=====================================================

When considering nutritional therapy for ICU patients, three main decisions must be made on the basis of the patient\'s medical condition, as indicated in the algorithm provided (Figure [3](#F3){ref-type="fig"}): (1) route of feeding - enteral versus parenteral; (2) when to feed - begin within 24 to 48 hours of ICU admission preferred (early enteral feeding); and (3) what to feed - a standared enteral formula or one with targeted functional ingredients (anti-inflammatory, immune-modulating, or tolerance-promoting nutrients).

![**For ICU patients, this algorithm guides how, when, and what feeding formulation to select in order to improve outcomes**. It highlights targeted use of anti-inflammatory and immune-modulating formulas, as well as tolerance-promoting formulas. ALI, acute lung injury; AOX, anti-oxidants; ARDS, acute respiratory distress syndrome; ARG, arginine; BMI, body mass index; GI, gastrointestinal; GLN, glutamine; IV, intravenous; ω-3, omega-3 fatty acids.](cc10430-3){#F3}

This nutrition algorithm is intended as a guide for choosing the right therapeutic nutrition formula; as always, clinical judgment also plays a very important role in decision-making. In choosing, clinicians may need to consider other factors, such as whether formula cost is a limiting factor and what to choose when conditions coincide - for example, sepsis and GI intolerance. In addition, the health and nutritional status of a patient can change rapidly - for example, a trauma patient develops sepsis. As a result, the nutritional needs of a critically ill patient should be reassessed routinely and often.

Conclusions
===========

Nutrition - given early and by the enteral route - is now well established in the ICU. We believe future ICU nutrition algorithms need to focus on evidence-based therapeutic nutrition as a new standard of care. In our opinion, the modern ICU clinician now has the opportunity to make full use of specialized nutrition in the ICU, that is, formulas supplemented with anti-inflammatory, immune-modulating, and tolerance-promoting nutrients. Each formula type contains a combination of pharmaconutrients that have the potential to enhance natural recovery processes, prevent or blunt certain disease-related complications, and provide vital energy as well-tolerated macronutrients. Antioxidant vitamins and minerals, arginine, glutamine, certain ω-3 long-chain fatty acids, hydrolyzed proteins, and medium-chain triglycerides are functional nutrients. By providing full macro- and micronutrient support along with these pharmaconutrients, therapeutic nutrition offers fresh hope for improved outcomes in ICU patients.
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